but without active ingredients.
Sponsors
Inmunotek S.L.
Conditions
Aetiological treatment of moderate to severe rhinitis/rhinoconjunctivitis with or without mild to moderate controlled allergic asthmaAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthma
Phase 3
Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of sublingual immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae_MM09-SLG-058
RecruitingCTIS2023-505918-14-00
Start: 2025-07-16Target: 147Updated: 2025-05-20
Prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive tree
Not yet recruitingCTIS2024-514525-34-00
Target: 180Updated: 2025-12-02
Prospective, multicentre, randomized, double-blind, placebo-controlled, clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and cupressaceae
RecruitingCTIS2024-514524-16-00
Start: 2021-05-11Target: 180Updated: 2025-09-05